Adaptimmune Therapeutics plc (ADAP): Price and Financial Metrics
ADAP Price/Volume Stats
| Current price | $1.06 | 52-week high | $2.05 |
| Prev. close | $1.08 | 52-week low | $0.42 |
| Day low | $1.04 | Volume | 565,527 |
| Day high | $1.10 | Avg. volume | 1,754,812 |
| 50-day MA | $1.38 | Dividend yield | N/A |
| 200-day MA | $0.90 | Market Cap | 1.05B |
ADAP Stock Price Chart Interactive Chart >
Adaptimmune Therapeutics plc (ADAP) Company Bio
Adaptimmune Therapeutics plc is a clinical stage biopharmaceutical company focused on novel cancer immunotherapy products based on its T-cell receptor platform. The company was founded in 2014 and is based in Abingdon, the United Kingdom.
Latest ADAP News From Around the Web
Below are the latest news stories about ADAPTIMMUNE THERAPEUTICS PLC that investors may wish to consider to help them evaluate ADAP as an investment opportunity.
Positive week for Adaptimmune Therapeutics plc (NASDAQ:ADAP) institutional investors who lost 68% over the past yearKey Insights Institutions' substantial holdings in Adaptimmune Therapeutics implies that they have significant... |
Adaptimmune Completes Submission of Rolling Biologics License Application (BLA) to U.S. FDA for Afami-cel for the Treatment of Advanced Synovial SarcomaFirst BLA for an engineered T-cell therapy for solid tumors submitted to U.S. Food and Drug AdministrationAfami-cel data demonstrate better outcomes for people with synovial sarcoma compared to historical control data; pivotal trial has met primary endpoint for efficacyPhiladelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - December 6, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, today announced the completion of the submission o |
Adaptimmune (ADAP) Rises as GSK Transfers T-Cell Therapy INDAdaptimmune (ADAP) shares rise as GSK transfers IND for letetresgene autoluecel (lete-cel), which is being developed for treating synovial sarcoma and myxoid/round cell liposarcoma. |
Adaptimmune Receives Transfer of IND for Lete-cel ProgramInterim analysis of pivotal IGNYTE-ESO trial demonstrates 40% response rate in people with synovial sarcoma or myxoid/ round cell liposarcoma Company will lay out plans for its cell therapy sarcoma franchise including afami-cel and lete-cel in January 2024Philadelphia, Pennsylvania. and Oxford, United Kingdom--(Newsfile Corp. - November 29, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, announces the transfer of the IND for letetresgene autoluecel |
Adaptimmune Therapeutics PLC (ADAP) Loses -28.34% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerAdaptimmune Therapeutics PLC (ADAP) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. |
ADAP Price Returns
| 1-mo | -30.26% |
| 3-mo | 45.21% |
| 6-mo | 92.73% |
| 1-year | -22.06% |
| 3-year | -81.17% |
| 5-year | -78.05% |
| YTD | 33.67% |
| 2023 | -45.68% |
| 2022 | -61.07% |
| 2021 | -30.43% |
| 2020 | 349.17% |
| 2019 | -79.13% |
Continue Researching ADAP
Here are a few links from around the web to help you further your research on Adaptimmune Therapeutics PLC's stock as an investment opportunity:Adaptimmune Therapeutics PLC (ADAP) Stock Price | Nasdaq
Adaptimmune Therapeutics PLC (ADAP) Stock Quote, History and News - Yahoo Finance
Adaptimmune Therapeutics PLC (ADAP) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...